At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
LGX818drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
In Brief
A Phase 2 clinical trial evaluating LGX818 for Melanoma. Completed, enrolled 7 participants across 5 sites.
Detailed Summary
The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsArray BioPharma
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionMar 2016
TodayJul 2026
First PostedJul 10, 2013
Enrollment StartJul 1, 2013
Primary CompletionMar 17, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.0 years ago
Interventions
LGX818drug